Key facts
- It has raised $13.7M; the latest was Later Stage VC ($13.7M) in Jan 2025.
- Notable investors include QF Capital, Prosperico Ventures, China Taiping Insurance Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for RocGene
- ·The full record, as it builds
Funding rounds
No funding rounds for RocGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RocGene
Developer of DNA Testing equipment designed for scientific research users of the hospital. The company is committed to introducing the leading biological instruments to China and providing more advanced technologies and services for Chinese biological scientific research users.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- rocgene.com/
- Ownership
- Privately Held (backing)
RocGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RocGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RocGene in its N-PORT filings yet. We sweep new filings monthly.